Investor Relations
Edison Oncology was founded in 2018 by experienced life science industry veterans to develop and commercialize new therapies targeting the fight against cancer. Our mission is to develop and commercialize novel cancer therapies to improve the lives of cancer patients and their families.
Symbol
Nasdaq : FORPrice
$Volume
Change
Company Overview
seeks to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual and institutional investor includes stock price and history, upcoming events and presentations and financial documents. Edison Oncology is traded on The NASDAQ under the symbol ABCD.
Latest News
Presentations
You are about to review presentations, reports and/or filings of Edison Oncology that contain time-sensitive information. The information contained therein is only accurate as of the date thereof. Edison Oncology will not be reviewing or updating the material that is contained in these items after the date thereof. The information contained therein may be updated, amended, supplemented or otherwise altered by subsequent presentations, reports and/or filings by Edison Oncology.
Quarterly Results
Q4 2024 Results | December 31, 2024